For three years running, the results of Nice Insight’s annual Pharmaceutical and Biotechnology Outsourcing Survey1 have revealed a steady rise in the percentage of respondents who work at traditional pharma companies engaged in the development of biopharmaceuticals. In addition, expenditure on the outsourcing of biologics activities by these companies significantly exceeds that on small-molecule projects.
At the same time, traditional pharma companies are looking for more collaborative relationships with CROs and CMOs that are recognised for high quality. And while pricing is not considered a crucial factor when choosing a service provider, cost-effectiveness is a key criterion when traditional pharma companies evaluate the performance of CROs and CMOs.
Cost-effectiveness is a key criterion when traditional pharma companies evaluate the performance of CROs and CMOs
The increase in the percentage of respondents who work for traditional pharmaceutical companies that are involved in the development of biotherapeutics has occurred across all three segments tracked by Nice Insight’s survey: emerging pharma, medium-sized and speciality pharma, and Big Pharma.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.